Michael Chiorean, MD
The selective, oral sphingosine 1-phosphate receptor modulator etrasimod was significantly more effective than placebo in inducing clinical and endoscopic response in a study of more than 150 patients with moderate to severe ulcerative colitis.
In the phase 2 OASIS trial, investigator Michael Chiorean, MD, the director of the IBD Center of Excellence at Virginia Mason’s Digestive Disease Institute in Seattle, and his colleagues randomly assigned 156 patients with